Drugs / DOR/3TC/TDF
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04375800 | Feb 2021 → Nov 2028 expected | HIV infectious disease | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DOR/3TC/TDF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04375800 ↗ |
| Route | Oral | “Administered orally” NCT04375800 ↗ |